Form 4: United Therapeutics Executive Exercises and Sells Shares Under 10b5-1 Plan

Paul A. Mahon, EVP & General Counsel at United Therapeutics, executed a pre-arranged 10b5-1 plan involving the exercise of share tracking awards and subsequent sale of common stock.

Summary

• Paul A. Mahon, an executive at United Therapeutics, engaged in transactions involving the company's stock.
• On November 21, 2024, Mahon exercised 7,700 share tracking awards at a price of $163.30.
• Concurrently, Mahon sold 7,700 shares of common stock at a price of $367.36.
• These transactions were executed under a pre-arranged 10b5-1 trading plan established on June 20, 2024.
• Following these transactions, Mahon directly owns 36,710 shares of common stock and 52,750 share tracking awards.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction by an executive under a pre-arranged plan, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who use 10b5-1 plans to manage their stock holdings and avoid accusations of insider trading. It is common for executives to exercise stock options or awards and sell shares for personal financial management.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard practice among publicly traded companies to allow insiders to trade shares without violating insider trading laws.
• The exercise and sale of shares by executives is a common occurrence, and the specific prices and quantities are unique to the individual's compensation and financial planning.
• Comparable companies would have similar filings when their executives exercise options or sell shares under pre-arranged plans.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged plan and do not indicate a change in the company's fundamentals.

Key Dates

Keywords

share tracking awards, 10b5-1 plan, insider trading, stock sale, executive compensation, UTHR, United Therapeutics